Postoperative	O
progression	O
of	O
pulmonary	B-Organ
metastasis	O
in	O
osteosarcoma	B-Cancer
.	O

Early	O
relapse	O
with	O
distant	O
metastasis	O
often	O
is	O
observed	O
in	O
patients	O
with	O
cancer	B-Cancer
after	O
resection	O
of	O
the	O
primary	B-Cancer
tumor	I-Cancer
.	O

It	O
is	O
considered	O
that	O
resection	O
of	O
the	O
primary	B-Cancer
tumor	I-Cancer
induces	O
activation	O
of	O
systemic	O
angiogenesis	O
and	O
enhances	O
progression	O
of	O
remote	O
metastasis	O
.	O

The	O
authors	O
show	O
that	O
resection	O
of	O
the	O
primary	B-Cancer
osteosarcoma	I-Cancer
tumor	I-Cancer
enhances	O
progression	O
of	O
pulmonary	B-Organ
metastasis	O
in	O
animal	O
osteosarcoma	B-Cancer
models	O
.	O

Matrigel	O
plug	O
neovascularization	O
assay	O
revealed	O
that	O
systemic	O
angiogenic	O
activity	O
was	O
elevated	O
after	O
primary	B-Cancer
tumor	I-Cancer
removal	O
(	O
tumor	B-Cancer
intact	O
group	O
,	O
1	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
21	O
g	O
/	O
dL	O
;	O
tumor	B-Cancer
removed	O
group	O
,	O
4	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
35	O
g	O
/	O
dL	O
)	O
.	O

In	O
addition	O
,	O
serum	B-Organism_substance
concentration	O
of	O
the	O
angiogenesis	O
inhibitor	O
,	O
endostatin	O
,	O
decreased	O
significantly	O
after	O
primary	B-Cancer
tumor	I-Cancer
removal	O
.	O

Treatment	O
with	O
the	O
antiangiogenic	O
reagent	O
TNP	O
-	O
470	O
suppressed	O
postoperative	O
progression	O
of	O
pulmonary	B-Organ
metastasis	O
.	O

These	O
results	O
indicate	O
the	O
possibility	O
that	O
activation	O
of	O
angiogenic	O
activity	O
after	O
resection	O
of	O
osteosarcoma	B-Cancer
tumors	I-Cancer
enhances	O
progression	O
of	O
pulmonary	B-Organ
metastasis	O
.	O

The	O
current	O
data	O
also	O
suggest	O
that	O
administration	O
of	O
antiangiogenic	O
reagents	O
can	O
prevent	O
progression	O
of	O
pulmonary	B-Organ
metastasis	O
in	O
osteosarcoma	B-Cancer
postoperatively	O
.	O

